Identification of MMP1 as a potential gene conferring erlotinib resistance in non-small cell lung cancer based on bioinformatics analyses
Abstract Background Non-small cell lung cancer (NSCLC) is the major type of lung cancer with high morbidity and poor prognosis. Erlotinib, an inhibitor of epidermal growth factor receptor (EGFR), has been clinically applied for NSCLC treatment. Nevertheless, the erlotinib acquired resistance of NSCL...
Main Authors: | Huyue Zhou, Qiumei Xiang, Changpeng Hu, Jing Zhang, Qian Zhang, Rong Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-07-01
|
Series: | Hereditas |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s41065-020-00145-x |
Similar Items
-
Erlotinib induces the human non–small‐cell lung cancer cells apoptosis via activating ROS‐dependent JNK pathways
by: Fenglian Shan, et al.
Published: (2016-11-01) -
Synergistic Induction of Erlotinib-Mediated Apoptosis by Resveratrol in Human Non-Small-Cell Lung Cancer Cells by Down-Regulating Survivin and Up-Regulating PUMA
by: Peipei Nie, et al.
Published: (2015-04-01) -
Combination chemotherapy with intermittent erlotinib and pemetrexed for pretreated patients with advanced non-small cell lung cancer: a phase I dose-finding study
by: Minami Seigo, et al.
Published: (2012-07-01) -
Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study
by: Meng-Xia Li, et al.
Published: (2017-04-01) -
DNA Polymerase Alpha Subunit B Is a Binding Protein for Erlotinib Resistance in Non-Small Cell Lung Cancer
by: Tae Young Kim, et al.
Published: (2020-09-01)